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Background: There is increasing ambiguity towards national mammographic screening programs due to varying
publicized estimates of overdiagnosis, i.e., breast cancer that would not have been diagnosed in the women’s
lifetime outside screening. This analysis compares the cumulative incidence of breast cancer in screened and
unscreened women in Norway from the start of the fully implemented Norwegian Breast Cancer Screening
Program (NBCSP) in 2005.
Methods: Subjects were 53 363 women in the Norwegian Women and Cancer (NOWAC) study, aged 52–79 years,
with follow-up through 2010. Mammogram and breast cancer risk factor information were taken from the most
recent questionnaire (2002–07) before the start of individual follow-up. The analysis differentiated screening into
incidence (52–69 years) and post screening (70–79 years). Relative risks (RR) were estimated by Poisson regression.
Results: The analysis failed to detect a significantly increased cumulative incidence rate in screened versus
other women 52–79 years. RR of breast cancer among women outside the NBCSP, the “control group”, was
non-significantly reduced by 7% (RR = 0∙93; 95% confidence interval 0∙79 to 1∙10) compared to those in the
program. The RR was attenuated when adjusted for risk factors; RRadj = 0∙97 (0∙82 to 1∙15). The control group
consisted of two subpopulations, those who only had a mammogram outside the program (RRadj =1∙04; 0∙86 to 1∙26)
and those who never had a mammogram (RRadj = 0∙77; 0∙59 to 1∙01). These groups differed significantly with respect
to risk factors for breast cancer, partly as a consequence of the prescription rules for hormone therapy which indicate
a mammogram.
Conclusions: In the fully implemented NBCSP, no significant difference was found in cumulative incidence rates of
breast cancer between NOWAC women screened and not screened. Naïve comparisons of screened and unscreened
women may be affected by important differences in risk factors. The current challenge for the screening program is to
improve the diagnostics used at prevalence screenings (ages 50–51).
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The public discussion following a large number of
scientific articles related to overdiagnosis in national
mammographic screening programs for breast cancer
has become a major concern both for national screening
programs and women deciding to participate. In the
context of screening, overdiagnosis is the discovery of* Correspondence: eiliv.lund@uit.no
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reproduction in any medium, provided the orcancers that without screening would not have been
diagnosed and consequently treated in a woman’s life-
time [1,2]. The main problem is the lack of diagnostic
procedures that can subclassify breast tumors into over-
diagnostic and clinically important invasive cancers
which would obviate overtreatment. This limitation has
forced researchers to try many different approaches to
estimate the overdiagnosis [3-14]. An independent meta-
analysis of three clinical trials reported a 19% increased
incidence of breast cancer among screened women dur-
ing the screening period and an 11% increased incidencetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Estimates based on ecological analyses are heteroge-
neous [6,8,9,11-13]. A major weakness of ecological
analyses is the inability to adequately [15] control for the
confounding effect of hormone therapy (HT). In Norway,
as in most other countries, public guidelines for prescrib-
ing HT include an initial mammogram or participation in
a national screening program [16,17]. Thus, the partici-
pants in the program will more often be users of HT.
Since HT users have a higher risk of breast cancer [18,19],
some of the estimated overdiagnosis might be due to the
more extensive HT use among screening program par-
ticipants. In addition, HT can reduce both mammogram
sensitivity and specificity due to high breast density associ-
ated with HT use [20].
Estimates of overdiagnosis have included either only
invasive cancers, or both invasive and ductal carcinoma
in situ (DCIS) which are most often identified through
mammography. Several recent cohort analyses were
published from Norway [2], Denmark [21], and Italy [22]
using a record linkage design with information on
screening invitations or participations from program
registries, and outcomes from cancer registries. The
estimated overdiagnosis varied from almost zero to
around ten percent when the years after the end of
active screening were included. Individual level data
were used to examine overdiagnosis in Norway, resulting
in overdiagnosis estimates between 10 and 20 percent
[2]. None of the studies had access to information on
mammograms taken outside the program or necessary
information for control of confounders or assessment of
risk factors.
While the historical development of the screening
program in Norway and many other countries has been
used for estimating overdiagnosis, the core question for
women entering the system today is the current and
future level of risk of overdiagnosis in the national on-
going program. The Norwegian Breast Cancer Screening
Program (NBCSP) has operated on a national scale since
2005 [23]. When estimating the consequence of partici-
pating in a mammographic screening program, three
different screening phases are identified. First, preva-
lence screening occurs during the first participation. In
the NBCSP, all women are first invited at 50 or 51 years
of age. Later screening examinations (52–69 years),
based on both the clinical and mammographic examina-
tions compared to previous ones, give an incidence
screening. Finally, the “compensatory drop” in the years
after the age of 69 when the women are no longer
offered screening. Since screening should detect cancers
earlier than normally identified, there is expected to be a
drop in the incidence when screening is stopped [10].
This analysis uses the national population based
cohort Norwegian Women and Cancer study (NOWAC)to compare cumulative breast cancer incidence rates
among women with different mammography histories
between 52 and 79 years of age using incidence data for
2005–2010.
Methods
Norwegian Breast Cancer Screening Program (NBCSP)
The NBCSP started in 1996 as an evaluation project in
four counties, but later expanded to the entire country
[24]. It follows European guidelines with mammograms
obtained in two views and each read independently by
two radiologists. In 2005, the program was fully imple-
mented in most of the country, but first invitations to the
program were still being sent to all age groups (50–69) in
two small counties: Hedmark and Vestfold. Starting in
2006, the screening program was fully implemented and
all women were first invited to the program at 50 or
51 years. In 2006, there were 28 375 women with first
invitations to the NBCSP, including 25 357 (89%) at ages
50–51, 1361 (5%) at ages 52–53 and the rest (6%) in
older age groups (Cancer Registry of Norway, unpub-
lished data). Women are then invited back every two
years through age 69.
Norwegian Women and Cancer (NOWAC)
NOWAC was initiated in 1991 [25]. Questionnaires
were mailed to women randomly selected from the
national population register held by Statistics Norway
during 1991–2007. For each woman the unique person
number, name, and address were extracted. Before
mailing the letter of information and the questionnaire,
the person number was replaced by a serial number that
was the only identification on the questionnaire. The
overall response rate for NOWAC questionnaires is 62%.
All linkages between NOWAC members and national
registries were done by Statistics Norway based on the
unique person number.
The NOWAC questionnaires include information
about mammography as well as lifestyle and social-
demographics. During 2002–2005, the questionnaires
included detailed questions about the type of mammo-
gram. Women were asked if they had a mammogram
and if so, how many were through an invitation to the
NBCSP, through a referral from their doctor, or without
an invitation or referral. Ninety-one percent of women
aged 52 or older at the time of their submitted question-
naire answered these detailed mammography questions.
Women who indicated that they had at least one
examination via NBCSP invitation were considered as
participating in the mammography program. During
2005–2007, after the nationwide implementation of the
NBCSP, the referral questions were removed and instead
women were asked how many years it had been since
their last mammography examination. The change in
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on participation could be taken from the screening
register held by the Cancer Registry of Norway. How-
ever, this detailed information has not been available
to researchers on an individual level, with a recent
exception [2].
Although the questions about mammography were
asked only once, the answers for women over age 52
were stable indicators of mammography patterns. A
random subset of NOWAC participants who were asked
about their mammography history in 2003 received
another questionnaire during 2010–2011. For those who
were 52 years or more at the time of the first question-
naire and answered a second questionnaire (N = 7361),
93% of those who reported never having had a mammo-
gram on the first questionnaire had the same response.
The answers regarding programmed mammograms were
also robust. Of those indicating participation in the
NBCSP, 83% responded the same 7 years later and for
those indicating that they only had mammograms out-
side the NBCSP, 78% responded the same 7 years later.
Sample selection
The NOWAC Cohort includes 172 478 women between
the ages of 30 and 70 at recruitment who were randomly
selected from the Norwegian population. A subset of
these women were selected to form a Mammography
Evaluation Cohort for this study. The sample was re-
stricted to women who completed a NOWAC question-
naire during 2002–2007 at an age of 52 or higher and
who lived in a county with a fully implemented screen-
ing program. These restrictions ensured that women in
the study would have received at least one invitation to
participate in the screening program prior to the
questionnaire, thus determining which women were
participating in the nation screening. The evaluation
cohort also excluded women with a diagnosis of invasive
breast cancer or DCIS prior to their questionnaire, and
those who did not answer the mammography questions.
The Mammography Evaluation Cohort includes 53 363
women divided into three groups based upon their
mammography history. The “never had a mammogram”
group includes all women who reported only “No” to
the questions about mammogram history. Since the
Mammography Evaluation Cohort necessarily precludes
women in the prevalence screening (ages 50–51) in
order to accurately identify those participating in the
program, previously published rates for invasive breast
cancer and DCIS for Norwegian women aged 50–51
were used for comparison [2].
Person-years and follow-up
The number of people at risk for having a breast cancer
diagnosis during 2005–2010 was calculated at the personlevel. Person-years (PY) were based on date of entrance
into the study, age group, and date of exit from the study
(date of invasive breast cancer diagnosis, death, or end
of follow-up on 31 December 2010). Follow-up data
during 2005–2010 came from the Cancer Registry of
Norway and the Cause of Death Registry. Women in the
Mammography Evaluation Cohort had an average
follow-up time of 5∙6 years (median 6∙0) for a total of
300 016 PY, and 972 incident diagnoses of breast cancer
(Table 1). The majority of these diagnoses were invasive
breast cancer (89%) with the remaining DCIS (11%). The
participation rate in the NBCSP for the cohort was 75%,
which is similar to previously reported national partici-
pation rates of 76% [23]. As a randomly selected cohort,
NOWAC participants have similar age-specific incidence
rates as national figures [26] for 2006–2010 (Figure 1).
NOWAC participants 65–69 years had a slightly higher
incidence rate than those nationally, but the cumulative
incidence rates were similar. The incidence rates for
those in the Mammography Evaluation Cohort, the
current study population, are representative of the
overall cohort and thus comparable to national rates
(dashed line in Figure 1; ages 55–79). For DCIS, the
incidence rates were closely correlated.
Statistical analyses
Characteristics of the Mammography Evaluation Cohort
groups were compared using chi-square tests of independ-
ence. Confidence intervals for the age-specific breast
cancer incidence rates were calculated assuming a Poisson
distribution [27]. Cumulative incidence rates for ages
52–79 were calculated as the cumulated sums of the
age-specific incidence rates. Rates for each age were
estimated from rates calculated for each age group
assuming a constant rate within each group [28]. Log
rank tests were used to compare cumulative incidence
rates between groups. Age-adjusted relative risks and
their 95% confidence intervals were estimated using
Poisson regression with robust error variance [29].
The NOWAC questions before 2005 made it possible
to perform the analyses taking into account three
groups: the program group of women with at least one
mammogram in the NBCSP, the outside group of women
with mammograms only outside the screening program,
and the never group of women who reported never hav-
ing a mammogram. The last two groups were combined
into a “control” or reference group for comparison with
women participating in the screening program in order
to be comparable with other analyses of program
screened versus a control group. Estimates of relative
risks were adjusted for major risk factors for breast can-
cer taken from the woman’s most recent questionnaire.
All statistical analyses were conducted in SAS version 9∙2
(SAS Incorporated, Cary, NC, USA). Statistical significance
Table 1 Age-specific breast cancer cases, person-years and rates for the Mammography Evaluation Cohort from the
Norwegian Women and Cancer Study, 2005-2010
52-55 56-59 60-64 65-69 70-74 75-79
Total (N = 53363) Invasive 47 246 343 162 33 32
Invasive + DCIS 53 267 400 181 35 36
PY 22840 85593 114108 42796 20319 14360
Rate 232 312 351 423 172 251
Program (N = 42285) Invasive 35 206 284 130 26 19
Invasive + DCIS 38 225 334 147 28 21
PY 17674 70331 94926 33452 15045 8569
Rate 215 320 352 439 186 245
Outside program (N = 6479) Invasive 6 28 42 22 3 6
Invasive + DCIS 8 30 49 24 3 8
PY 2238 9244 12568 6069 3302 2724
Rate 357 325 390 395 91 294
Never (N = 4599) Invasive 6 12 17 10 4 7
Invasive + DCIS 7 12 17 10 4 7
PY 2929 6017 6615 3274 1972 3067
Rate 239 199 257 305 203 228
DCIS = ductal carcinoma in situ.
PY = person-years.
Rates per 100,000 PY.
Program = received at least one mammogram within the screening program.
Outside program = received a mammogram, but only outside the screening program.
Never = never had a mammogram.
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than 0∙05.
Results
The distribution of lifestyle factors related to breast
cancer risk (Table 2) shows several distinct differences.Figure 1 Age-specific invasive and ductal carcinoma in situ (DCIS) bre
figures, the Norwegian Women and Cancer Study and the MammographyWomen who never had a mammogram tended to be
older than those in the other groups, had more children,
were less likely to have had a maternal history of breast
cancer, and most distinctly, were less likely to be current
users of HT (12% versus 25% for those in the program
and 32% for those with mammograms outside theast cancer incidence rates 2006–2010. Lines represent national
Evaluation Cohort.
Table 2 Characteristics of the Mammography Evaluation Cohort from the Norwegian Women and Cancer Study by
mammogram history, 2005-2010
Program* Outside program Never
N 42285 6479 4599
Age in 2005 N = 42276 N = 6476 N = 4440
52-55 23∙8% 19∙9% 25∙9%
56-59 36∙0% 31∙4% 24∙6%
60-64 26∙1% 24∙2% 19∙3%
65-69 7∙2% 11∙2% 8∙5%
70-74 5∙0% 6∙9% 8∙1%
75-79 2∙0% 6∙4% 13∙7%
Parity N = 42285 N = 6479 N = 4599
none 7∙4% 7∙0% 8∙5%
1-2 52∙0% 52∙1% 43∙1%
3-4 36∙7% 36∙4% 40∙0%
5+ 4∙0% 4∙5% 8∙4%
Age at first birth N = 38904 N = 5983 N = 4170
<20 12∙0% 13∙3% 16∙4%
20-24 50∙6% 51∙1% 51∙6%
25-29 27∙9% 26∙9% 23∙3%
30-34 7∙1% 6∙4% 6∙3%
35+ 2∙4% 2∙3% 2∙5%
Body mass index N = 41054 N = 6288 N = 4369
<18.5 1∙1% 1∙0% 2∙2%
18.5-24,9 51∙4% 51∙4% 48∙8%
25-29,9 35∙2% 36∙5% 35∙1%
30+ 12∙2% 11∙1% 13∙8%
Education N = 40113 N = 6033 N = 4159
Primary (≤10) 38∙9% 41∙0% 51∙2%
Secondary (11–12) 29∙3% 29∙6% 23∙8%
College (≥13) 31∙8% 29∙4% 25∙0%
Maternal history of breast cancer 5% 8% 3%
Currently use hormone therapy 25% 32% 12%
*Program = received at least one mammogram within the screening program.
Outside program = received a mammogram, but only outside the screening program.
Never = never had a mammogram.
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group, i.e., those who had a mammogram outside the
program and those who never had a mammogram, were
statistically significant for all risk factors (p < 0∙05).
The age-specific incidence rates for the program group
versus the control group showed similar rates across the
study interval 52–79 years (Figure 2). Women who had
a mammogram in the program and those who did not
both demonstrated increasing rates of incident breast
cancer during ages 52–69, although this was most
evident in those who participated in the NBCSP. The
drop in incidence rates for women over 69 years was
clearly shown for both groups and was in the order
of 200/100 000 PY from the preceding age group.
Values for ages 50–51 are previously published ratesof invasive breast cancer and DCIS for Norwegian
women who attended the NBCSP during 1995–2009
(394/100 000 PY) and for those invited but who did
not attend (211/100 000 PY) [2].
The cumulative incidence rates of invasive breast
cancer and DCIS for women in the program and those
in the control group were similar over the age-groups
52–79 years (Figure 3; p = 0∙47). The cumulative rate
ratio for ages 52–79 was 1∙05 between the program and
control groups. If the previously published rates for ages
50–51 are included, then the cumulative rate ratio for
ages 50–79 is 1∙09 between the program and control
groups. When examined separately, the heterogeneity of
the control group becomes evident. Women who repor-
ted never having had a mammogram had the lowest
Figure 2 Age-specific breast cancer rates and 95% confidence intervals by mammogram history. Data for the Mammography Evaluation
Cohort are from the Norwegian Women and Cancer Study, 2005–2010. The control group includes women who reported never having had a
mammogram, and women who only had mammograms outside the screening program. Vertical lines separate prevalence screening (ages 50–51),
incidence screening (ages 52–69), and follow-up (ages 70–79). The rates for ages 50–51 are from Falk et al. [2]. The last age category includes 10 years
due to small numbers.
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significantly different than those in the screening pro-
gram (p = 0∙07). Women who reported only having had
mammograms outside the screening program had the
highest cumulative rate of breast cancer. Notably, theFigure 3 Cumulative breast cancer rates by mammogram history. Dat
Women and Cancer Study, 2005–2010. The control group includes women
only had mammograms outside the screening program.only significant difference in cumulative rates of cancer
was between women who had mammograms outside the
program and those who never had mammograms, i.e.,
between the two groups in the ‘control’ group (p = 0∙05).
When cumulative rates of only invasive breast cancersa for the Mammography Evaluation Cohort are from the Norwegian
who reported never having had a mammogram, and women who
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same although the differences in cumulated rates for
ages 52–79 are much smaller among the groups.
The age-adjusted relative risks of having a breast can-
cer diagnosis for those who never had a mammogram
compared with those in the program group showed a
marginally-significant 23% reduced risk (RR = 0∙77; 95%
CI: 0∙59 to 1∙01) (Table 3). The results were non-
significant and attenuated after adjusting for important
risk factors (RRadj = 0∙82, 0∙61 to 1∙11). Women who had
received a mammogram only outside the screening
program had a slightly higher, although also non-
significant, age-adjusted relative risk for a breast cancer
diagnosis compared to those in the screening program
(RRadj = 1∙04, 0∙86 to 1∙26). The combined group of all
women without a screening program mammogram
(never had a mammogram or only outside screening)
versus the program group showed an age-adjusted rela-
tive risk of 0∙93 (0∙79 to 1∙10). Further adjustments for
risk factors attenuated the estimate; 0∙97 (0∙82 to 1∙15).
Discussion
This analysis did not show a significantly increased cu-
mulative incidence rate in screened women versus other
women from NOWAC in age-groups covering 52–
79 years. Relative risks of those not screened compared
with screened showed a 7% decreased risk, although
non-significant. After adjusting for risk factors, theTable 3 Age-adjusted relative risk (RR) of breast cancer: estim
Invasive and DCIS Never/outside pr
Age adjusted* 0∙93 (0∙79, 1∙1
Additionally adjusted for:
Parity 0∙94 (0∙80, 1∙1
Hormone therapy use 0∙93 (0∙79, 1∙1
Maternal history of cancer 0∙93 (0∙79, 1∙0
Body mass index (<25, 25+) 0∙95 (0∙80, 1∙1
Education (primary, secondary, college) 0∙96 (0∙81, 1∙1
Full model 0∙97 (0∙82, 1∙1
Invasive only Never/outside pr
Age adjusted* 0∙96 (0∙81, 1∙1
Additionally adjusted for:
Parity 0∙96 (0∙81, 1∙1
Hormone therapy use 0∙96 (0∙81, 1∙1
Maternal history of cancer 0∙96 (0∙81, 1∙1
Body mass index (<25, 25+) 0∙97 (0∙82, 1∙1
Education (primary, secondary, college) 0∙99 (0∙83, 1∙1
Full model 1∙00 (0∙84, 1∙2
Mammography Evaluation Cohort data are from the Norwegian Women and Cance
reference group. RR calculated for women who reported never having a mammogr
program (outside program).
*Age groups: 52–55, 56–59, 60–64, 65–69, 70–79.decreased risk was 3%. The control group, which did not
participate in the screening program, included two quite
different subpopulations: those who never had a mam-
mogram, and those who only had them outside the pro-
gram. These subpopulations differed significantly on risk
factors and although the cumulative risk of breast cancer
for those with mammograms outside the program was
higher compared with those who never had a mammo-
gram, the difference was non-significant.
The results and interpretations have some limitations.
First, the cohort is small. This is clearly demonstrated in
the analysis of different subgroups. Second, the infor-
mation on screening participation was based on a
self-report questionnaire of mammography history. It
is unknown if some women in the control group may
have had a screening program mammogram after
their last questionnaire, although the small retest group
suggests low bias. A source of systematic bias could be the
introduction of digital technology between 2004 and 2011.
This could give an additional prevalence screening in all
age-groups dependent on the introduction in the different
counties. The introduction was gradual and the last
counties changed in 2011 (Cancer Registry of Norway,
unpublished data).
On the other hand, NOWAC is one of very few
national representative cohorts that can be used for the
analysis of an ongoing screening program. The results
clearly demonstrate the problem of comparing a controlates and 95% confidence intervals
ogram Never Outside program
0) 0∙77 (0∙59, 1∙01) 1∙04 (0∙86, 1∙26)
0) 0∙78 (0∙59, 1∙02) 1∙04 (0∙86, 1∙26)
0) 0∙81 (0∙62, 1∙06) 1∙01 (0∙83, 1∙22)
9) 0∙78 (0∙59, 1∙01) 1∙02 (0∙84, 1∙24)
2) 0∙77 (0∙58, 1∙01) 1∙06 (0∙87, 1∙28)
4) 0∙77 (0∙58, 1∙03) 1∙07 (0∙88, 1∙30)
5) 0∙82 (0∙61, 1∙11) 1∙05 (0∙86, 1∙28)
ogram Never Outside program
4) 0∙85 (0∙65, 1∙12) 1∙03 (0∙84, 1∙26)
5) 0∙86 (0∙65, 1∙03) 1∙02 (0∙84, 1∙26)
4) 0∙90 (0∙69, 1∙18) 0∙99 (0∙81, 1∙22)
3) 0∙86 (0∙65, 1∙12) 1∙01 (0∙83, 1∙25)
6) 0∙85 (0∙64, 1∙12) 1∙05 (0∙85, 1∙29)
8) 0∙86 (0∙65, 1∙15) 1∙06 (0∙86, 1∙31)
0) 0∙93 (0∙69, 1∙25) 1∙04 (0∙84, 1∙29)
r cohort, 2005–2010. Women in the mammogram screening program are the
am (never) and those who only had mammograms outside the screening
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control group concept. The control group in Norway
consisted of women either with mammograms taken
outside the program as a consequence of diagnostic
procedures or opportunistic screening, and those with-
out any mammograms. The relative structure of these
groups might differ from country to country and over
time, invalidating ecological analyses. The importance of
the weights of the three groups was clearly related to the
systematic differences in risk factors and by the under-
lying incidence rates. The most important was the
confounding by current use of HT, which could be a
serious bias in ecological analyses due to its known
carcinogenic properties [30].
Another systematic selection bias between the two
groups could be due to the Norway action plan for
surveillance of breast cancer in carriers of certain BRCA
mutations or evidence of risk of hereditary breast cancer
without documented mutations [31]. This plan calls for
annual mammograms for women from as young as 25
through age 60 and is independent of the NBCSP. Thus,
these women are included in the group who had
mammograms outside the NBCSP, and could explain the
high prevalence of a maternal history of breast cancer of
8% in this group versus 3% among those who reported
never having taken a mammogram. This differential
prevalence of women with a maternal history of breast
cancer could partially explain the differences in incidence.
The analysis included two age-related groups and
background data on a third covering the ages of
screening and a 10-year post-screening follow-up. The
previously published data for the prevalence screening
(ages 50–51) indicated that screened women had twice
the rate of breast cancer during these ages as those who
did not attend screening. Our analysis of the inci-
dence screening (52–69 years) showed no significant
differences according to mammogram history. There
was a drop in breast cancer rates following the end
of screening for both those screened and those not
participating in the NBCSP, possibly related to repeated
screenings outside the NBCSP for those in the con-
trol group.
The cumulative incident rates for the individual mam-
mography histories elucidated the differences within the
control group. Those who never had a mammogram had
the lowest cumulative rate for ages 52–79, while those
who only had mammograms outside the NBCSP had
the highest cumulative rate. Although not significantly
different, these subtle differences in cumulative rates
mirror the significant differences in risk factors obser-
ved. These findings suggest that ecological comparisons
among self-selected groups of mammography attendees
may be misleading if they fail to account for the hetero-
geneity within the unscreened population.Other approaches for the analysis of the Norwegian
screening program used a cohort design with counties as
proxy for individual information on screening partici-
pation [3]. This gave an overdiagnosis of 25% in the age-
range 50–69 years or 15% including the “compensatory
drop”. Again, the analysis was based on the assumption
of a control group without knowledge of the use of
mammography in that group. The Cancer Registry of
Norway [2] recently estimated overdiagnosis in the order
of 10-13% for invasive breast cancer and 14-20% for
both DCIS and invasive breast cancers depending on if
women were only invited to mammography or had
multiple screening visits. The analysis was based on indi-
vidual information on screening status in the national
screening program, but did not examine risk factors.
The discrepancies towards the estimates given based on
the older clinical trials [1] could be due to the improve-
ment in diagnostics over time. The estimate of overdiag-
nosis in the present analysis is lower than both with the
UK independent estimate [1] and the estimate from the
Cancer Registry of Norway [2], but did not include
prevalence diagnoses. Given these published overdiag-
nosis estimates that included prevalence screenings, the
high rates of breast cancer cases during ages 50–51, and
our non-significant findings during ages 52–69, the data
suggest that most overdiagnosis may occur during the
prevalence screenings.
Conclusions
The results from the present analysis differ from previous
studies due to the focus on recent, modern screening in
the context of the Norwegian health care system and with
proper adjustment for important confounders. Future
work on overdiagnosis should include examination of risk
factors, especially use of HT, when providing estimates.
The findings support that women participating in the
ongoing, national mammographic screening program of
breast cancer after its complete installment might only
have overdiagnosis related to the prevalence screening.
This should lead to a more careful diagnostic work-up for
women during the initial prevalence screening and careful
considerations of necessary treatment.Consent
All women have filled in an informed consent for later
linkages to the Cancer Registry of Norway, the Norwegian
Breast Cancer Screening Program, and the register of
death certificates in Statistics Norway as well as the use of
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